Tag
In ENZA‑p (ANZUP1901) substudy, baseline PSMA PET total tumour volume (PSMA‑TTV) was strongly prognostic for overall survival and predicted greater OS benefit from adding 177Lu‑PSMA‑617 to enzalutamide; PSMA SUVmean was not predictive.
Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematol
Final TALAPRO-2 data show that adding talazoparib to enzalutamide improves overall survival and rPFS in metastatic castration‑resistant prostate cancer, with the largest benefit in BRCA1/2‑altered tumors; hematologic toxicity is common but
The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast
